What's Happening?
Prelude Growth Partners has invested $20 million in OneSkin, a biotech-driven skin longevity brand. Founded by female PhD scientists, OneSkin focuses on extending skinspan, the period during which skin remains healthy and functional, by targeting the underlying mechanisms of aging. The investment marks a significant milestone for OneSkin, enabling the brand to expand its resources and further its mission. OneSkin's proprietary peptide, OS-01, aims to reduce senescent cells, which contribute to aging and inflammation. Prelude Growth's investment reflects confidence in OneSkin's innovative approach and potential to become a leading brand in the skin longevity category.
AD
Why It's Important?
The investment in OneSkin underscores the growing interest in longevity science and its application in skincare. As consumers increasingly seek products that offer more than surface-level benefits, brands like OneSkin are positioned to lead the market with scientifically-backed solutions. This development highlights the potential for biotech innovations to transform the beauty industry, offering new avenues for growth and differentiation. Prelude Growth's involvement signals strong investor confidence in the skin longevity category, potentially attracting further investments and partnerships in the sector.
